Fair chance of nod for first NASH therapy in USA, says GlobalData

26 January 2023
lab_test_biotech_research_2021_big

Pharma industry analyst GlobalData has highlighted the strength of data supporting a submission from US biotech Intercept Pharmaceuticals (Nasdaq: ICPT) in non-alcoholic steatohepatitis (NASH).

Intercept Pharmaceuticals (Nasdaq: ICPT) is developing obeticholic acid (OCA) as a treatment for people with pre-cirrhotic liver fibrosis due to NASH, and the US regulator is currently reviewing data from the trial program.

The company has had a bumpy ride to get to this point, with the US Food and Drug Administration issuing a Complete Response Letter (CRL) regarding an earlier submission.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Pharmaceutical